Vol 5, No 4 (2014)
Review paper
Published online: 2015-03-06

open access

Page views 620
Article views/downloads 2682
Get Citation

Connect on Social Media

Connect on Social Media

The role of bendamustine in chronic lymphocytic leukemia with particular focus on the treatment of elderly patients

Krzysztof Warzocha, Ewa Lech-Marańda, Bożena Katarzyna Budziszewska, Marek Dudziński, Dariusz Wołowiec, Andrzej Pluta, Sławomira Kyrcz-Krzemień, Iwona Hus, Tadeusz Robak
Hematologia 2014;5(4):285-295.

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia diagnosed in adults. Selecting the proper treatment regimen, and its intensity should be adjusted individually for each patient — most of them are over 65 years-old and have often multiple comorbidities. Bendamustine (BEN) is rediscovered cytotoxic agent combining physicochemical and pharmacological properties of alkylating agents and purine analogues. This article focuses on the presentation of the substance, the analysis of effectiveness of BEN in CLL and the assessment of the drug safety profile and its role in the treatment of patients with CLL.




Hematology in Clinical Practice